首页> 外文OA文献 >Computational analysis of Human Immunodeficiency Virus (HIV) Type-1 reverseudtranscriptase crystallographic models based on significant conserved residuesudfound in Highly Active Antiretroviral Therapy (HAART)-treated patients.
【2h】

Computational analysis of Human Immunodeficiency Virus (HIV) Type-1 reverseudtranscriptase crystallographic models based on significant conserved residuesudfound in Highly Active Antiretroviral Therapy (HAART)-treated patients.

机译:人类免疫缺陷病毒(HIV)1型反向 ud的计算分析显着保守残基的转录酶晶体学模型 ud在高效抗逆转录病毒疗法(HAART)治疗的患者中发现。

摘要

Reverse transcription of the viral single-stranded (+) RNA genome into double-stranded DNA is an essential step in the human immunodeficiency virus' (HIV) life-cycle. Although several viral proteins are involved in the regulation and/or efficiency of reverse transcription, the process of retroviral DNA synthesis is entirely dependent on the enzymatic activities of the retroviral reverse transcriptase enzyme (RT). Due to its crucial role in the HIV life-cycle, RT is a primary target for anti-HIV drug development. Nonetheless, drug resistance is the major problem affecting the clinical efficacy of antiretroviral agents. Incomplete pharmacological pressure represents the logical cause and not the consequence of different mutation pathways in RT associated with approved inhibitors resistance.ududIn this review we have analyzed RT Protein Data Bank (PDB) models using our innovative computational approach “GRID Based Pharmacophore Model” (GBPM). This method was applied to clinically relevant RT conserved residues found in a large cohort of HAART treated patients. The PDB entries have been selected among the unbound and the complexed models with DNA and/or inhibitors. Such an approach has revealed itself useful to highlight the mutation effects in the drug-RT recognition as well as in the heterodimer stabilization of the enzyme. Most of the clinical and biochemical evidences already reported in the literature have been rationalized at molecular level via the GBPM computational approach. A definite future application of this method will be the identification of conserved regions of critical macromolecules, such as the HIV-1 RT, to be targeted for the development of innovative therapeutic agents.
机译:将病毒单链(+)RNA基因组逆转录成双链DNA是人类免疫缺陷病毒(HIV)生命周期中必不可少的步骤。尽管几种病毒蛋白参与逆转录的调控和/或效率,但是逆转录病毒DNA合成的过程完全取决于逆转录病毒逆转录酶(RT)的酶活性。由于其在HIV生命周期中的关键作用,RT是抗HIV药物开发的主要目标。但是,耐药性是影响抗逆转录病毒药物临床疗效的主要问题。不完全的药理学压力代表了合理的原因,而不是与批准的抑制剂耐药相关的RT中不同突变途径的结果。 ud ud在本综述中,我们使用创新的计算方法“基于GRID的药理模型”分析了RT蛋白质数据库(PDB)模型”(GBPM)。该方法应用于在大量接受HAART治疗的患者中发现的临床相关的RT保守残基。已从具有DNA和/或抑制剂的未绑定模型和复杂模型中选择了PDB条目。这样的方法已经显示出其自身在突出药物-RT识别以及酶的异二聚体稳定中的突变作用方面有用。文献中已报道的大多数临床和生化证据已通过GBPM计算方法在分子水平上得到了合理化。该方法未来的明确应用将是鉴定关键性大分子的保守区域,例如HIV-1 RT,以开发创新型治疗剂为目标。

著录项

相似文献

  • 外文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号